Denosumab-Teva onco 120 mg / 1.7 ml
Denosumab-Teva onco 120 mg / 1.7 ml is a medicine authorised by Swissmedic under authorisation number 70132. The authorisation holder is Teva Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 10 December 2025 and the authorisation is limited until 09 December 2030. ATC code M05BX04 places the medicine in the group Drugs for treatment of bone diseases.
| Authorisation number | 70132 |
|---|---|
| Name | Denosumab-Teva onco 120 mg / 1.7 ml |
| Full name | Denosumab-Teva onco 120 mg / 1.7 ml, Injektionslösung |
| Authorisation holder | Teva Pharma AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | M05BX04 |
| First authorisation | 10 December 2025 |
| Authorisation validity | 09 December 2030 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Denosumab-Teva onco 120 mg / 1.7 ml, Injektionslösung | A | 10 December 2025 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Durchstechflasche(n) | M05BX04 | 07.16.1. | A |
| 2 | 3 | Durchstechflasche(n) | M05BX04 | 07.16.1. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Denosumab-Teva onco 120 mg / 1.7 ml authorised in Switzerland?
Yes. Denosumab-Teva onco 120 mg / 1.7 ml is authorised by Swissmedic under authorisation number 70132, data as of 01 September 2026. The authorisation is limited until 09 December 2030.
Which dispensing category does Denosumab-Teva onco 120 mg / 1.7 ml have?
Denosumab-Teva onco 120 mg / 1.7 ml is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Denosumab-Teva onco 120 mg / 1.7 ml?
The authorisation holder is Teva Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.